糖肾平胶囊对糖尿病肾病大鼠肾脏保护作用及其对肾组织TGF-β_1蛋白及mRNA表达的影响  

Effects of Tangshenping Capsule on the Renal Protection and Expressions of TGF-β_1 and mRNA in Streptozotocin-induced Diabetic Nephropathy Rats

作　　者：赵宗江[1] 豆小妮[1] 张新雪[1] 杨美娟[1] 

机构地区：[1]北京中医药大学细胞与生化实验室,北京100029

出　　处：《世界科学技术-中医药现代化》2010年第5期759-763,共5页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：北京市中医管理局"51510"资助项目(JJ2007-006):参芪糖肾安胶囊治疗糖尿病肾病的临床疗效观察及作用研究;负责人;张振中;国家自然科学基金面上项目(30973831):糖尿病肾病足细胞凋亡从"肾痿"论治与糖肾平胶囊干预机制的研究";负责人;赵宗江

摘　　要：目的:探讨糖肾平胶囊对糖尿病肾病大鼠肾脏保护作用及其对肾组织TGF-β1蛋白及mRNA表达的影响。方法:雄性SD大鼠,50只,按体重随机分为正常组10只,模型组40只。模型组大鼠按55mg·kg^(-1),腹腔一次性注射链脲佐菌素,72h后血糖≥16.7mmol·L^(-1),尿糖≥4+者为造模成功。将造模成功的大鼠按血糖高低随机分为模型组、厄贝沙坦组、糖肾平胶囊组。每周称体重,第4、8、12周分笼收集24h尿液检测24h尿蛋白定量。用药12周,处死大鼠行血液生化指标BUN、Scr、TG检测及肾组织Mallory染色,观察生化指标和肾组织病理形态学改变,采用免疫组织化、原位杂交方法观察分析肾组织TGF-β_1蛋白及mRNA的表达情况。结果:模型组大鼠摄食减少、精神不振、活动迟缓、尿量减少、体重减轻、24h尿蛋白定量增高、肾脏病理改变等,而糖肾平胶囊组对以上指标均有不同程度改善,并优于厄贝沙坦组;正常组及用药组肾小管上皮细胞、肾间质细胞胞浆有轻度TGF-β_1蛋白及mRNA表达,模型组则呈强阳性表达。糖肾平胶囊组与模型组比,TGF-β_1蛋白及mRNA表达明显减少(P<0.05)。结论:糖肾平胶囊可通过对肾组织TGF-β_1蛋白及mRNA表达下调而发挥治疗和预防糖尿病肾病的作用。This work aimed to observe the Effects of ＂Tangshenping Capsule＂ on the renal protection and expressions of TGF-β1 and mRNA in streptozotocin-induced diabetic nephropathy rats. 50 SD rats were randomly divided into the normal control group （n=10） and the model group （n = 40）. The rat model was established by an intraperitoneal injection of streptozotocin at 55 mg/kg. Glucose ≥ 16.7 mmol/L and urinary glucose ≥ 4＋ after 72 h was considered as diabetes modeling success. Then modeling success rats were re-divided into the model group, the irbesartan group and the Tangshenping capsule group. Body weight was weighed every week, 24 h urinate was collected at week 4, 8 and 12, and 24 h Urine protein was detected. The rats were sacrificed 12 weeks after the administration. Mallory staining was carried out for biochemical indicator BUN, Scr and TG, and the pathological changes of renal tissue were observed. Renal tissue TGF-β1 protein and mRNA expression were examined by immunohistochemistry and hybridization analysis. The model groups had different levels of decreased feeding and sleeping, slow activity, volume reduction, weight loss, increased 24 h urinary protein, abnormal blood biochemical indicators, and DN pathological changes, while the irbesartan and Tangshenping capsule group had the above factors improved in varying degrees, and the Tangshenping capsule group was superior to the irbesartan group. The model group showed DN pathological changes in the renal tissue; the normal group and the treatment group had slight TGF-β1 and mRNA expression in tubular epithelial cells of renal and renal interstitial cells, while the model group had a strong expression. Compared with the model group, the Tangshenping capsule group showed significantly reduced TGF-β1 and mRNA expression （P〈0.05）. Taken together, Tangshenping capsule may function in the treatment and prevention of DN via regulating the TGF-β1 and mRNA balance.

关 键 词：糖尿病肾病TGF—β1糖肾平胶囊 大鼠 

分 类 号：R285.5[医药卫生—中药学]